Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, steady-state study of Tenofovir (TFV) and Emtricitabine (FTC)
pharmacokinetics (PK) in transgender women taking feminizing hormones. Half of the
participants will be transgender women on feminizing hormones, the other half will be male
volunteers not taking any hormone therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir